The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.
The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.
The PREVAIL study evaluated the...